Trial Search Results

Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease

Provide patients with serious AdV infection or disease access to treatment with BCV.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Chimerix

Stanford Investigator(s):

Intervention(s):

  • Drug: Brincidofovir

Eligibility


Inclusion Criteria:

   - Confirmed serious AdV infection based on clinical symptoms and laboratory testing
   showing AdV in the blood or other bodily fluids

   - Able to swallow medication, either tablet or liquid

Exclusion Criteria:

   - Previous dosing with Brincidofovir

   - If female, not pregnant or trying to become pregnant

Ages Eligible for Study

2 Months - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting